Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

Esther S. Oh; Christopher M. Marano; Jeannie Marie Leoutsakos; Rebecca W. Lee; Robert A. Rissman; Gwenn S. Smith; Suzanne Craft; Constantine G. Lyketsos

doi:10.1016/j.dadm.2015.06.002

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

Esther S. Oh, Christopher M. Marano, Jeannie Marie Leoutsakos, Rebecca W. Lee, Robert A. Rissman, Gwenn S. Smith, Suzanne Craft, Constantine G. Lyketsos

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Introduction: Plasma levels of amyloid-beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment [MCI]) from normal controls. Methods: A total of 57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2-hour period. Changes in plasma Aβ40 and 42 levels were measured from either baseline or 5 minutes to the 10-minute time-point. Results: Compared with normal controls, subjects with AD/MCI had significantly less change (δ) in plasma levels for both Aβ40 (-3.13 [40.93] vs. 41.34 pg/mL [57.16]; P = .002) and Aβ42 (-0.15 [3.77] vs. 5.64 pg/mL [10.65]; P = .004). Discussion: OGTT combined with measures of plasma Aβ40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.

Original language	English (US)
Pages (from-to)	311-315
Number of pages	5
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	1
Issue number	3
DOIs	https://doi.org/10.1016/j.dadm.2015.06.002
State	Published - Sep 1 2015

Keywords

Alzheimer's disease
Blood biomarker
Oral glucose tolerance test

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1016/j.dadm.2015.06.002

Cite this

@article{c9a76aeb7ada438da4e070a401c159b6,

title = "Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker",

abstract = "Introduction: Plasma levels of amyloid-beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment [MCI]) from normal controls. Methods: A total of 57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2-hour period. Changes in plasma Aβ40 and 42 levels were measured from either baseline or 5 minutes to the 10-minute time-point. Results: Compared with normal controls, subjects with AD/MCI had significantly less change (δ) in plasma levels for both Aβ40 (-3.13 [40.93] vs. 41.34 pg/mL [57.16]; P = .002) and Aβ42 (-0.15 [3.77] vs. 5.64 pg/mL [10.65]; P = .004). Discussion: OGTT combined with measures of plasma Aβ40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.",

keywords = "Alzheimer's disease, Blood biomarker, Oral glucose tolerance test",

author = "Oh, {Esther S.} and Marano, {Christopher M.} and Leoutsakos, {Jeannie Marie} and Lee, {Rebecca W.} and Rissman, {Robert A.} and Smith, {Gwenn S.} and Suzanne Craft and Lyketsos, {Constantine G.}",

note = "Funding Information: This study was supported by R21AG0337695 ( NIA / NIH ), AG038893 , MH086881 the Rosalinde and Arthur Gilbert Foundation /AFAR New Investigator Award in Alzheimer's disease, and the Hobson Gift Fund . E.S.O. was also supported by 5KL2RR025006, 1K23AG043504-01 (NIA/NIH), P50 AG005146, the Roberts Gift Fund, the Ossoff Family Fund. This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR) which is funded in part by grant number UL1 TR 001079 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The authors thank Dr Pattie Green for her contribution and Shannon Campbell (ADCS Biomarker Core, UCSD) for technical assistance with bioassays. Publisher Copyright: {\textcopyright} 2015 The Authors.",

year = "2015",

month = sep,

day = "1",

doi = "10.1016/j.dadm.2015.06.002",

language = "English (US)",

volume = "1",

pages = "311--315",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Oral glucose tolerance testing to modulate plasma amyloid levels

T2 - A novel biomarker

AU - Oh, Esther S.

AU - Marano, Christopher M.

AU - Leoutsakos, Jeannie Marie

AU - Lee, Rebecca W.

AU - Rissman, Robert A.

AU - Smith, Gwenn S.

AU - Craft, Suzanne

AU - Lyketsos, Constantine G.

N1 - Funding Information: This study was supported by R21AG0337695 ( NIA / NIH ), AG038893 , MH086881 the Rosalinde and Arthur Gilbert Foundation /AFAR New Investigator Award in Alzheimer's disease, and the Hobson Gift Fund . E.S.O. was also supported by 5KL2RR025006, 1K23AG043504-01 (NIA/NIH), P50 AG005146, the Roberts Gift Fund, the Ossoff Family Fund. This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR) which is funded in part by grant number UL1 TR 001079 from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. The authors thank Dr Pattie Green for her contribution and Shannon Campbell (ADCS Biomarker Core, UCSD) for technical assistance with bioassays. Publisher Copyright: © 2015 The Authors.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Introduction: Plasma levels of amyloid-beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment [MCI]) from normal controls. Methods: A total of 57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2-hour period. Changes in plasma Aβ40 and 42 levels were measured from either baseline or 5 minutes to the 10-minute time-point. Results: Compared with normal controls, subjects with AD/MCI had significantly less change (δ) in plasma levels for both Aβ40 (-3.13 [40.93] vs. 41.34 pg/mL [57.16]; P = .002) and Aβ42 (-0.15 [3.77] vs. 5.64 pg/mL [10.65]; P = .004). Discussion: OGTT combined with measures of plasma Aβ40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.

AB - Introduction: Plasma levels of amyloid-beta (Aβ) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in Aβ plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment [MCI]) from normal controls. Methods: A total of 57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2-hour period. Changes in plasma Aβ40 and 42 levels were measured from either baseline or 5 minutes to the 10-minute time-point. Results: Compared with normal controls, subjects with AD/MCI had significantly less change (δ) in plasma levels for both Aβ40 (-3.13 [40.93] vs. 41.34 pg/mL [57.16]; P = .002) and Aβ42 (-0.15 [3.77] vs. 5.64 pg/mL [10.65]; P = .004). Discussion: OGTT combined with measures of plasma Aβ40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.

KW - Alzheimer's disease

KW - Blood biomarker

KW - Oral glucose tolerance test

UR - http://www.scopus.com/inward/record.url?scp=84939206628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939206628&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2015.06.002

DO - 10.1016/j.dadm.2015.06.002

M3 - Article

C2 - 26413562

AN - SCOPUS:84939206628

SN - 2352-8729

VL - 1

SP - 311

EP - 315

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

IS - 3

ER -

Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this